Outlook Therapeutics Inc
(XTER:41O)
€
0
0 (0%)
Market Cap: 166.81 Mil
Enterprise Value: 333.06 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 28/100 - Q2 2024 Outlook Therapeutics Inc Earnings Call TranscriptMay 16, 2024Earnings
- Outlook Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference TranscriptNov 07, 2023
- Outlook Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Outlook Therapeutics Inc Corporate Update Call TranscriptAug 30, 2023
- Outlook Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Outlook Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 14, 2023
- Outlook Therapeutics Inc at JTC Team Investor CEO Spotlight Event (Virtual) TranscriptMay 11, 2022
- Outlook Therapeutics Inc to Discuss Results from Its Pivotal Phase 3 NORSE TWO Call TranscriptAug 03, 2021
- Outlook Therapeutics Inc R&D Day (Virtual) TranscriptMay 20, 2021
- Outlook Therapeutics Inc at JTC Virtual Investor KOL Roundtable TranscriptOct 29, 2020
- Outlook Therapeutics Inc Reports Topline Results for ONS-5010 from NORSE 1 Call TranscriptAug 20, 2020
- Outlook Therapeutics Inc Virtual Investor Summit TranscriptApr 22, 2020
- Outlook Therapeutics Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference TranscriptFeb 11, 2020
Sorry the transcript is not found. Please try another one.